Drugs to treat Inflammatory bowel diseases raise lymphoma risk

A study published online in The Lancet suggests that patients who took certain drugs in an effort to keep inflammatory bowel diseases in remission may have a significantly higher risk of developing certain lymphomas.

What diseases were being treated?

Inflammatory bowel diseases such as Crohn's disease or ulcerative colitis.

What drugs were given?

Thiopurines such as Mercaptopurine (aka 6-mercaptopurine, 6-MP, Purinethol) and Azathioprine (aka Azasan, Imuran).

What's the risk for these patients?

In all, patients seemed to have a five-fold increased risk of lymphomas, compared with those who had never taken the drugs.

What's the conclusion?

The authors of the study concluded that the benefits of thiopurines in keeping the original diseases in remission outweigh the risks of developing lymphoma.

Source: medpagetoday.com

Blog Category: 

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap